Podcasts about Wellcome

Audio FileGround Truths can also be found on Apple Podcasts, Spotify and YouTube.The UK is the world leader in human genomics, and laid the foundation for advancing medicine with the UK Biobank, Genomes England and now Our Future Health (w/ 5 million participants). Sir John Bell is a major force in driving and advising these and many other initiatives. After 22 years as the Regius Professor of Medicine at the University of Oxford he left in 2024 to be President of the Ellison Institute of Technology. Professor Bell has been duly recognized in the UK: knighted in 2015 and appointed Companion of Honor in 2023. In our conversation, you will get a sense for how EIT will be transformational for using A.I. and life science for promoting human health.Transcript with audio links Eric Topol (00:06):Hello, this is Eric Topol from Ground Truths. And I'm really delighted to welcome today, Sir John Bell who had an extraordinary career as a geneticist, immunologist, we'll talk about several initiatives he's been involved with during his long tenure at University of Oxford, recently became head of the Ellison Institute of Technology (EIT) in the UK. So welcome, John.Sir John Bell (00:30):Thanks, Eric. Thanks very much for having me.Eric Topol (00:34):Well, I think it's just extraordinary the contributions that you have made and continue to make to advance medicine, and I thought what we could do is get into that. I mean, what's interesting, you have had some notable migrations over your career, I think starting in Canada, at Stanford, then over as Rhodes Scholar in Oxford. And then you of course had a couple of decades in a very prestigious position, which as I understand was started in 1546 by King Henry VII, and served as the Regius Professor of Medicine at the University of Oxford. Do I have that right?Sir John Bell (01:11):It was actually Henry VIII, but you were close.Eric Topol (01:14):Henry VIII, that's great. Yeah. Okay, good. Well, that's a pretty notable professorship. And then of course in recent times you left to head up this pretty formidable new institute, which is something that's a big trend going on around the world, particularly in the US and we'll talk about. So maybe we can start with the new thing. Tell us more about the Ellison Institute of Technology (EIT), if you will.Sir John Bell (01:47):Yeah. So as you know, Larry Ellison has been one of the great tech entrepreneurs focused really on developing terrific databases over his career and through Oracle, which is the company that he founded. And Larry is really keen to try and give back something substantial to the world, which is based on science and technology. So he and I did quite a bit together over the Covid pandemic. He and I talked a lot about what we're doing and so on. He came to visit afterwards and he had, I think he decided that the right way to make his contributions would be to set up an institute that would be using the state-of-the-art science and technology with a lot of AI and machine learning, but also some of the other modern tools to address the major problems in healthcare, in food security, in green energy and climate change and in global governance.Sir John Bell (02:49):So anyway, he launched this about 18 months ago. He approached me to ask whether I would run it. He wanted to set it up outside Oxford, and he wanted to do something which is a bit different than others. And that is his view was that we needed to try and create solutions to these problems which are commercially viable and not all the solutions are going to be commercially viable, but where you can create those, you make them sustainable. So the idea is to make sure that we create solutions that people want to buy, and then if they buy them, you can create a sustainable solution to those issues. So we are actually a company, but we are addressing many of the same problems that the big foundations are addressing. And the big issues that you and I talk about in health, for example, are all on our list. So we're kind of optimistic as to where this will go and Larry's supporting the project and we're going to build out an institute here which will have about 5,000 people in it, and we'll be, I think a pretty exciting new addition to the science and technology ecosystem globally.Eric Topol (04:02):Well, I know the reverberations and the excitement is palpable and some of the colleagues I've spoken to, not just in England, but of course all over the world. So congratulations on that. It was a big move for you to leave the hardcore academics. And the other thing I wanted to ask you, John, is you had distinguished your career in immunology, in genetics, type 1 diabetes and other conditions, autoimmune conditions, and now you've really diversified, as you described with these different areas of emphasis at the new institute. Is that more fun to do it or do you have deputies that you can assign to things like climate change in other areas?Sir John Bell (04:50):Trust me, Eric, I'm not making any definitive decisions about areas I know nothing about, but part of this is about how do you set up leadership, run a team, get the right people in. And I have to say one of the really interesting things about the institute is we've been able to recruit some outstanding people across all those domains. And as you know, success is almost all dependent on people. So we're really pretty optimistic we're going to have a significant impact. And of course, we also want to take risks because not a lot of point in us doing stuff that everybody else is doing. So we're going to be doing some things that are pretty way out there and some of them will fail, so we are just going to get used to trying to make sure we get a few of them across the finish line. But the other thing is that, and you've experienced this too, you never get too old to learn. I mean, I'm sucking up stuff that I never thought I would ever learn about, which is fun actually, and really marvel.Eric Topol (05:55):It's fantastic. I mean, you've really broadened and it's great that you have the runway to get these people on board and I think you're having a big building that's under construction?Sir John Bell (06:07):Yeah, we've got the original building that Larry committed to is about 330,000 square feet of space. I mean, this is completely amazing, but we are of course to accommodate up to 5,000 people, we're going to need more than that. So we are looking at a much wider campus here that'll involve more than just that building. I think we'll end up with several million square feet of space by the time we're finished. So mean, it's a really big project, but we've already made progress in some domains to try and get projects and the beginnings of companies on the road to try and solve some of the big problems. So we're quite excited about it.Eric Topol (06:49):Now you, I assume it's pretty close to Oxford, and will you have some kind of inter interactions that are substantial?Sir John Bell (06:58):Yeah, so the university's been terrific about this actually, because of course most universities would say, well, why don't you do it inside the university and just give us the money and it'll all be fine. So of course Larry. Larry wasn't born yesterday, so I said, well, thank you very much, but I think we'll probably do this nearby. But the university also realized this is a really exciting opportunity for them and we've got a really good relationship with them. We've signed an agreement with them as to who will work where. We've agreed not to steal a lot of their staff. We're going to be bringing new people into the ecosystem. Some of the university people will spend some time with us and sometime in the university, so that will help. But we're also bringing quite a few new people into the setting. So the university has been really positive. And I think one of the things that's attractive to the university, and you'll be familiar with this problem in the UK, is that we're quite good. The discovery science here is pretty good.Sir John Bell (08:06):And we do startups now at scale. So Oxford does lots of little startup companies in the biotech space and all the rest of it, but we never scale any of these companies because there isn't the depth of capital for scaling capital to get these things scaled. And so, in a way what we're trying to do here at Ellison actually avoids that problem because Larry knows how to scale companies, and we've got the financial support now. If we have things that are really successful, we can build the full stack solution to some of these problems. So I think the university is really intrigued as to how we might do that. We're going to have to bring some people in that know how to do that and build billion dollar companies, but it's sufficiently attractive. We've already started to recruit some really outstanding people. So as a way to change the UK system broadly, it's actually quite a good disruptive influence on the way the thing works to try and fix some of the fundamental problems.Eric Topol (09:07):I love that model and the ability that you can go from small startups to really transformative companies have any impact. It fits in well with the overall objectives, I can see that. The thing that also is intriguing regarding this whole effort is that in parallel we've learned your influence. The UK is a genomics world leader without any question and no coincidence that that's been your area of emphasis in your career. So we've watched these three initiatives that I think you were involved in the UK Biobank, which has had more impact than any cohort ever assembled. Every day there's another paper using that data that's coming out. There's Genomes England, and then now Our Future Health, which a lot of people don't know about here, which is well into the 5 million people enrollment. Can you tell us about, this is now 15 years ago plus when these were started, and of course now with a new one that's the biggest ever. What was your thinking and involvement and how you built the UK to be a world leader in this space?Sir John Bell (10:26):So if you turn the clock back 20 years, or actually slightly more than 25 years ago, it was clear that genomics was going to have a play. And I think many of us believed that there was going to be a genetic element to most of the major common disease turn out to be true. But at the time, there were a few skeptics, but it seemed to us that there was going to be a genetic story that underpinned an awful lot of human disease and medicine. And we were fortunate because in Oxford as you know, one of my predecessors in the Regius job was Richard Doll, and he built up this fantastic epidemiology capability in Oxford around Richard Peto, Rory Collins, and those folks, and they really knew how to do large scale epidemiology. And one of the things that they'd observed, which is it turns out to be true with genetics as well, is a lot of the effects are relatively small, but they're still quite significant. So you do need large scale cohorts to understand what you're doing. And it was really Richard that pioneered the whole thinking behind that. So when we had another element in the formula, which was the ability to detect genetic variation and put that into the formula, it seemed to me that we could move into an era where you could set up, again, large cohorts, but build into the ability to have DNA, interrogate the DNA, and also ultimately interrogate things like proteomics and metabolomics, which were just in their infancy at that stage.Sir John Bell (12:04):Very early on I got together because I was at that stage at the Nuffield Chair of Medicine, and I got together, Rory and Richard and a couple of others, and we talked a little bit about what it would look like, and we agreed that a half a million people late to middle age, 45 and above would probably over time when you did the power calculations, give you a pretty good insight in most of the major diseases. And then it was really a question of collecting them and storing the samples. So in order to get it funded at the time I was on the council of the MRC and George Radda, who you may remember, was quite a distinguished NMR physiologist here. He was the chief executive of the MRC. So I approached him and I said, look, George, this would be a great thing for us to do in the UK because we have all the clinical records of these people going back for a decade, and will continue to do that.Sir John Bell (13:01):Of course, we immediately sent it out to a peer review committee in the MRC who completely trashed the idea and said, you got to be joking. So I thought, okay, that's how that lasted. And I did say to George, I said, that must mean this is a really good idea because if it had gone straight through peer review, you would've known you were toast. So anyway, I think we had one more swing at peer review and decided in the end that wasn't going to work. In the end, George to his credit, took it to MRC council and we pitched it and everybody thought, what a great idea, let's just get on and do it. And then the Wellcome came in. Mark Walport was at the Wellcome at the time, great guy, and did a really good job at bringing the Wellcome on board.Sir John Bell (13:45):And people forget the quantum of money we had to do this at the time was about 60 million pounds. I mean, it wasn't astonishly small. And then of course we had a couple of wise people who came in to give us advice, and the first thing they said, well, if you ever thought you were really going to be able to do genetics on 500,000 people, forget it. That'll never work. So I thought, okay, I'll just mark that one out. And then they said, and by the way, you shouldn't assume you can get any data from the health service because you'll never be able to collect clinical data on any of these people. So I said, yeah, yeah, okay, I get it. Just give us the money and let us get on. So anyway, it's quite an interesting story. It does show how conservative the community actually is for new ideas.Sir John Bell (14:39):Then I chaired the first science committee, and we decided about a year into it that we really needed the chief executive. So we got Rory Collins to lead it and done it. I sat on the board then for the next 10 years, but well look, it was a great success. And as you say, it is kind of the paradigm for now, large genetic epidemiology cohorts. So then, as you know, I advise government for many years, and David Cameron had just been elected as Prime Minister. This was in about 2010. And at the time I'd been tracking because we had quite a strong genomics program in the Wellcome Trust center, which I'd set up in the university, and we were really interested in the genetics of common disease. It became clear that the price of sequencing and Illumina was now the clear leader in the sequencing space.Sir John Bell (15:39):But it was also clear that Illumina was making significant advances in the price of sequencing because as you remember, the days when it cost $5,000 to do a genome. Anyway, it became clear that they actually had technology that gets you down to a much more sensible price, something like $500 a genome. So I approached David and I said, we are now pretty sure that for many of the rare diseases that you see in clinical practice, there is a genetic answer that can be detected if you sequenced a whole genome. So why don't we set something up in the NHS to provide what was essentially the beginnings of a clinical service to help the parents of kids with various disabilities work out what's going on, what's wrong with their children. And David had had a child with Ohtahara syndrome, which as you know is again, and so David was very, he said, oh God, I'll tell you the story about how awful it was for me and for my wife Samantha.Sir John Bell (16:41):And nobody could tell us anything about what was going on, and we weren't looking for a cure, but it would've really helped if somebody said, we know what it is, we know what the cause is, we'll chip away and maybe there will be something we can do, but at least you know the answer. So anyway, he gave us very strong support and said to the NHS, can you please get on and do it? Again massive resistance, Eric as you can imagine, all the clinical geneticists said, oh my God, what are they doing? It's complete disaster, dah, dah, dah. So anyway, we put on our tin hats and went out and got the thing going. And again, they did a really good job. They got to, their idea was to get a hundred thousand genomes done in a reasonable timeframe. I think five years we set ourselves and the technology advance, people often underestimate the parallel development of technology, which is always going on. And so, that really enabled us to get that done, and it still continues. They're doing a big neonatal program at the moment, which is really exciting. And then I was asked by Theresa May to build a life science strategy because the UK, we do this stuff not as big and broad as America, but for a small country we do life sciences pretty well.Eric Topol (18:02):That's an understatement, by the way. A big understatement.Sir John Bell (18:04):Anyway, so I wrote the strategies in 2017 for Theresa about what we would do as a nation to support life sciences. And it was interesting because I brought a group of pharma companies together to say, look, this is for you guys, so tell us what you want done. We had a series of meetings and what became clear is that they were really interested in where healthcare was going to end up in the next 20 years. And they said, you guys should try and get ahead of that wave. And so, we agreed that one of the domains that really hadn't been explored properly, it was the whole concept of prevention.Sir John Bell (18:45):Early diagnosis and prevention, which they were smart enough to realize that the kind of current paradigm of treating everybody in the last six months of life, you can make money doing that, there's no doubt, but it doesn't really fix the problem. And so, they said, look, we would love it if you created a cohort from the age of 18 that was big enough that we could actually track the trajectories of people with these diseases, identify them at a presymptomatic stage, intervene with preventative therapies, diagnose diseases earlier, and see if we could fundamentally change the whole approach to public health. So we anyway, went back and did the numbers because of course at much wider age group, a lot of people don't get at all sick, but we thought if we collected 5 million people, we would probably have enough. That's 10% of the UK adult population.Sir John Bell (19:37):So anyway, amazingly the government said, off you go. We then had Covid, which as you know, kept you and I busy for a few years before we could get back to it. But then we got at it, and we hired a great guy who had done a bit of this in the UAE, and he came across and we set up a population health recruitment structure, which was community-based. And we rapidly started to recruit people. So we've now got 2.9 million people registered, 2.3 million people consented, and we've got blood in the bank and all the necessary data including questionnaire data for 1.5 million people growing up. So we will get to 5 million and it's amazing.Eric Topol (20:29):It is. It really is, and I'm just blown away by the progress you've made. And what was interesting too, besides you all weren't complacent about, oh, we got this UK Biobank and you just kept forging ahead. And by the way, I really share this importance of finally what has been a fantasy of primary prevention, which never really achieved. It's always, oh, after a heart attack. But that's what I wrote about in the Super Agers book, and I'll get you a copy.Sir John Bell (21:02):No, I know you're a passionate believer in this and we need to do a lot of things. So we need to work out what's the trial protocol for primary prevention. We need to get the regulators on board. We've got to get them to understand that we need diagnostics that define risk, not disease, because that's going to be a key bit of what we're going to try and do. And we need to understand that for a lot of these diseases, you have to intervene quite early to flatten that morbidity curve.Eric Topol (21:32):Yeah, absolutely. What we've learned, for example, from the UK Biobank is not just, of course the genomics that you touched on, but the proteomics, the organ clocks and all these other layers of data. So that gets me to my next topic, which I know you're all over it, which is AI.Eric Topol (21:51):So when I did the NHS review back in 2018, 2019, the group of people which were amazing that I had to work with no doubt why the UK punches well beyond its weight. I had about 50 people, and they just said, you know what? Yeah, we are the world leaders in genomics. We want to be the world leader in AI. Now these days you only hear about US and China, which is ridiculous. And you have perhaps one of the, I would say most formidable groups there with Demis and Google DeepMind, it's just extraordinary. So all the things that the main foci of the Ellison Institute intersect with AI.Sir John Bell (22:36):They do. And we, we've got two underpinning platforms, well actually three underpinning platforms that go across all those domains. Larry was really keen that we became a real leader in AI. So he's funded that with a massive compute capacity. And remember, most universities these days have a hard time competing on compute because it's expensive.Eric Topol (22:57):Oh yeah.Sir John Bell (22:58):So that is a real advantage to us. He's also funded a great team. We've recruited some people from Demis's shop who are obviously outstanding, but also others from around Europe. So we really, we've recruited now about 15 really outstanding machine learning and AI people. And of course, we're now thinking about the other asset that the UK has got, and particularly in the healthcare space is data. So we do have some really unique data sets because those are the three bits of this that you need if you're going to make this work. So we're pretty excited about that as an underpinning bit of the whole Ellison Institute strategy is to fundamentally underpin it with very strong AI. Then the second platform is generative biology or synthetic biology, because this is a field which is sort of, I hesitate to say limped along, but it's lacked a real focus.Sir John Bell (23:59):But we've been able to recruit Jason Chin from the LMB in Cambridge, and he is one of the real dramatic innovators in that space. And we see there's a real opportunity now to synthesize large bits of DNA, introduce them into cells, microbes, use it for a whole variety of different purposes, try and transform plants at a level that people haven't done before. So with AI and synthetic biology, we think we can feed all the main domains above us, and that's another exciting concept to what we're trying to do. But your report on AI was a bit of a turning point for the UK because you did point out to us that we did have a massive opportunity if we got our skates, and we do have talent, but you can't just do it with talent these days, you need compute, and you need data. So we're trying to assemble those things. So we think we'll be a big addition to that globally, hopefully.Eric Topol (25:00):Yeah. Well that's another reason why I am so excited to talk to you and know more about this Ellison Institute just because it's unique. I mean, there are other institutes as like Chan Zuckerberg, the Arc Institute. This is kind of a worldwide trend that we're seeing where great philanthropy investments are being seen outside of government, but none have the computing resources that are being made available nor the ability to recruit the AI scientists that'll help drive this forward. Now, the last topic I want to get into with you today is one that is where you're really grounded in, and that's the immune response.Eric Topol (25:43):So it's pretty darn clear now that, well, in medicine we have nothing. We have the white cell neutrophil to lymphocyte ratio, what a joke. And then on the other hand, we can do T and B cell sequencing repertoires, and we can do all this stuff, autoantibody screens, and the list goes on and on. How are we ever going to make a big dent in health where we know the immune system is such a vital part of this without the ability to check one's immune status at any point in time in a comprehensive way? What are your thoughts about that?Sir John Bell (26:21):Yeah, so you seem to be reading my mind there. We need to recruit you over here because I mean, this is exactly, this is one of our big projects that we've got that we're leaning into, and that is that, and we all experienced in Covid the ins and outs of vaccines, what works, what doesn't work. But what very clear is that we don't really know anything about vaccines. We basically, you put something together and you hope the trial works, you've got no intermediate steps. So we're building a really substantial immunophenotyping capability that will start to interrogate the different arms of the immune response at a molecular level so that we can use a combination of human challenge models. So we've got a big human challenge model facility here, use human challenge models with pathogens and with associated vaccines to try and interrogate which bits of the immune response are responsible for protection or therapy of particular immunologically mediated diseases or infectious diseases.Sir John Bell (27:30):And a crucial bit to that. And one of the reasons people have tried this before, but first of all, the depth at which you can interrogate the immune system has changed a lot recently, you can get a lot more data. But secondly, this is again, where the AI becomes important because it isn't going to be a simple, oh, it's the T-cell, it's going to be, well, it's a bit of the T cells, but it's also a bit of the innate immune response and don't forget mate cells and don't forget a bit of this and that. So we think that if we can assemble the right data set from these structured environments, we can start to predict and anticipate which type of immune response you need to stimulate both for therapy and for protection against disease. And hopefully that will actually create a whole scientific foundation for vaccine development, but also other kinds of immune therapy and things like cancer and potentially autoimmune disease as well. So that's a big push for us. We're just busy. The lab isn't set up. We've got somebody to run the lab now. We've got the human challenge model set up with Andy Pollard and colleagues. So we're building that out. And within six months, I think we'll be starting to collect data. So I'm just kind of hoping we can get the immune system in a bit more structured, because you're absolutely right. It's a bit pin the tail on the donkey at the moment. You have no idea what's actually causing what.Eric Topol (29:02):Yeah. Well, I didn't know about your efforts there, and I applaud that because it seems to me the big miss, the hole and the whole story about how we're going to advanced human health and with the recent breakthroughs in lupus and these various autoimmune diseases by just targeting CD19 B cells and resetting like a Ctrl-Alt-Delete of their immune system.Sir John Bell (29:27):No, it's amazing. And you wouldn't have predicted a lot of this stuff. I think that means that we haven't really got under the skin of the mechanistic events here, and we need to do more to try and get there, but there's steady advance in this field. So I'm pretty optimistic we'll make some headway in this space over the course of the next few years. So we're really excited about that. It's an important piece of the puzzle.Eric Topol (29:53):Yeah. Well, I am really impressed that you got all the bases covered here, and what a really exhilarating chance to kind of peek at what you're doing there. And we're going to be following it. I know I'm going to be following it very closely because I know all the other things that you've been involved with in your colleagues, big impact stuff. You don't take the little swings here. The last thing, maybe to get your comment, we're in a state of profound disruption here where science is getting gutted by a madman and his henchmen, whatever you want to call it, which is really obviously a very serious state. I'm hoping this is a short term hit, but worried that this will have a long, perhaps profound. Any words of encouragement that we're going to get through this from the other side of the pond?Sir John Bell (30:52):Well, I think regardless of the tariffs, the scientific community are a global community. And I think we need to remember that because our mission is a global mission, and we need to lean into that together. First of all, America is such a powerhouse of everything that's been done scientifically in the human health domain. But not only that, but across all the other domains that we work in, we can't really make the kind of progress that we need to without America being part of the agenda. So first of all, a lot of sympathy for you and your colleagues. I know it must be massively destabilizing for you, not be confident that the things that work are there to help you. But I'm pretty confident that this will settle down. Most of the science is for, well, all the science is really for public good, and I think the public recognizes it and they'll notice if it's not being prosecuted in the way that it has to be. And the global science community cannot survive without you. So we're all leaning in behind you, and I hope it will settle. One of my worries is that these things take years to set up and literally hours or minutes to destroy. So we can't afford to take years to set them back up again. So we do need to be a bit careful about that, but I still have huge confidence in what you guys can achieve and we're all behind you.Eric Topol (32:37):Well, that's really helpful getting some words of wisdom from you there, John. So this has been terrific. Thanks so much for joining, getting your perspective on what you're doing, what's important is so essential. And we'll stay tuned for sure.Sir John Bell (32:59):And come and visit us at the EIT, Eric. We'd be glad to see you.*******************************Some of the topics that John and I discussed—immunology, A.I., genomics, and prevention—are emphasized in my new book SUPER AGERS. A quick update: It will have a new cover after making the New York Times Bestseller list and is currently ranked #25 for all books on Amazon. Thanks to so many of you for supporting the book!Here are a few recent podcasts:Dax Shepard: Dr. Mike Sanjay Gupta ***********************Thanks for reading and subscribing to Ground Truths.If you found this interesting please share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths— newsletters, analyses, and podcasts—is free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

This episode of The Naked Scientists was brought to you in partnership with the health foundation Wellcome.In this edition of The Naked Scientists, we return to the world of fungi and why this is one of the most serious health threats you haven't heard of... Like this podcast? Please help us by supporting the Naked Scientists

This episode of The Naked Scientists was brought to you in partnership with the health foundation Wellcome. This week, the first in a two-part series on the hidden world of fungi. What we do - and don't - know about them, and how the fungal landscape is set to shift as our climate changes. Like this podcast? Please help us by supporting the Naked Scientists

40 years ago a hole was discovered in the ozone layer. It provoked an international effort to ban the chemicals that were destroying our protection from the sun. Tom Heap and Helen Czerski are joined by Jonathan Shanklin, one of the team that realised that CFC chemicals used in aerosol cans and refrigerants were helping to create a 20 million square kilometre hole in the ozone layer above Antarctica. Also on the panel they speak to Alice Bell, author of ‘Our Biggest Experiment: a history of the climate crisis' and head of policy, climate and health at Wellcome, and Bristol University's Professor Matt Rigby who helps monitor how well countries are sticking to their promises on protecting the ozone layer.They discuss the unparalleled international unity that swiftly banned the worst of the ozone-destroying chemicals, and ask why we can't come up with a similar solution for manmade climate change. Tom will be delving into the black market in refrigerants and meeting the South American detectives dedicated to hunting down the chemicals that still threaten the ozone layer and come with an enormous cost to the climate.Featuring contributions from:Jonathan Shanklin - Emeritus Fellow, British Antarctic SurveyMatthew Rigby - Professor of Atmospheric Chemistry, University of BristolAlice Bell - Head of Policy: Climate and Health, WellcomeProducer: Beth Sagar-Fenton Assistant Producer: Toby FieldRare Earth is produced in collaboration with the Open University

Hello all house music lovers ! Wellcome to the Next Episode of House Jam on Data Transmission Radio. I hope You will find cool my unreleased edits . And be ready to listen a few brand new hits. Here they are: Mistier - In You (Lost and Found) LA Rush & Nadine Randle - A Little Like This (Club Mix) Invida , Maneth, Nina Carr - Wicked Game (RADIO EDIT) Huge thanks to James Hype for sharing his edits And finally if you will listen to the end there is surprise from JUMP COMPLETE FT HARRIET ANNABELL with a dope track Crazy Things. Enjoy! ⚡️Like the Show? Click the [Repost] ↻ button so more people can hear it!

What does a pink puppet called Connie have to do with ethics? More than you might think. On this episode, I'm speaking with a lawyer, whose innovative approach to getting employees to engage in ethics, involved turning to something we all know from our childhood, a puppet.Episode SummaryThat lawyer and my guest on this episode is Fraser Simpson, Associate General Counsel at the Wellcome Trust.  He's on the show to me to tell me about a creative and award-winning approach to embedding ethics in organisations. Fraser and the team at Acteon Communications tackled the challenge of inspiring ethical decision-making in a world where written policies often fall short. Their solution? Connie, a hot pink puppet who represents a conscience, prompting employees to ask, "What would Connie do?" Fraser shares how Connie was born from a need to engage employees in meaningful, human-centred conversations about ethics and compliance. We delve into why traditional approaches often fail, how behavioural science can transform organisational cultures, and why creativity is a powerful tool for behaviour change. Whether you're in legal, compliance, or simply curious about innovation in professional settings, Fraser's insights are both practical and inspiring. Throughout our conversation, Fraser illustrates the power of storytelling, humour, and simplicity in sparking conversations that matter. Connie's journey—from a sketch to a living, breathing character—offers lessons for anyone trying to make complex ideas relatable and impactful.Guest BiographyFraser is the Associate General Counsel at the Wellcome Trust, one of the world's largest charitable foundations supporting science to tackle urgent health challenges. Fraser's work that we discuss on the show focuses on developing a business integrity framework that empowers employees to make sound decisions in moments that matter.With a background in law and a passion for creativity, Fraser has pioneered innovative approaches to compliance, including the development of Connie, a hot pink puppet that embodies ethics and inspires employees to think critically.He describes himself as a dad of two first and a lawyer second, drawing on everyday challenges and creativity to influence his professional work.AI-Generated Timestamped Summary of Key Points[00:00:02] Innovative Ethics Solution (14 Minutes)Fraser introduces Connie, a bright pink puppet created to make ethics training engaging and memorable. By using behavioural science, Wellcome Trust demonstrates the power of moving from dry rulebooks to fostering value-driven decisions. [00:14:05] Revolutionizing Ethics Engagement (8 Minutes)The importance of using creativity to influence ethical decision-making, rather than over rigid rules, focusing on empowering employees with adaptable tools. Fraser explains how storytelling helps make ethics relatable and impactful. [00:21:50] Bringing Connie to Life (13 Minutes)Fraser shares the playful inspiration behind Connie's creation, including how a Hetty vacuum cleaner sparked the idea and how he worked with Acteon, a behavioural science-driven agency. Connie balances humour and professionalism to spark meaningful conversations. [00:34:32] Communicating Ethics Through Creativity (11 Minutes)The Compliance team has considered how to deploy multi-sensory strategies, such as tactile tools and music, to make ethics training more engaging. These creative methods integrate ethics seamlessly into employees' daily routines. [00:45:05] Launching Connie and Sustaining Engagement (6 Minutes)Connie's debut redefines compliance training by prioritising empowerment over box-ticking. Strategies like in-person meetings and digital tools ensure Connie stays relevant across the organisation. [00:50:51] Encouraging Ethical Conversations (14 Minutes)Fraser discusses innovative training approaches, such as regular ethical dilemmas and the "What Would Connie Do?" framework. These quick, consistent exercises develop decision-making skills and foster lasting habits. [01:04:50] Balancing Compliance and Personal Accountability (12 Minutes)The conversation highlights the importance of personal agency in decision-making. By promoting thoughtful judgment, the approach helps create a culture of accountability and better choices. [01:16:23] Inclusive and Accessible Communication (12 Minutes)Inclusivity is central to the approach adopted by Wellcome, including the deployment of a Braille Code of Conduct and other accessible formats. Fraser explains how Wellcome developed practical tools, like a mobile app, for use in critical moments. [01:28:34] Connie's Global Reach and Future Potential (10 Minutes)Connie's cross-cultural appeal in compliance training is explored, along with the vision of e-Connie—a virtual companion for ethical decision-making on a global scale.LinksThe Wellcome Trust — https://wellcome.org/ Acteon, the firm that helped to design and develop Connie — https://www.acteoncommunication.com/ Acteon's case study of Connie — https://www.acteoncommunication.com/case-studies/meet-connie-your-conscience/ Sarah Abramson of Acteon pitching the idea of Connie at ECEC, the 2024 European Compliance & Ethics Conference — https://youtu.be/iCf1CklbysQ?si=z5-Vt3xcC2loZLB1&t=1641 Sarah's appearance on this podcast — https://www.humanriskpodcast.com/sarah-abramson-on-speaking-to-the-human/

Recorded December 5th, 2024. A hybrid seminar by Dr Lorraine Grimes (Maynooth University) as part of the Medical and Health Humanities Seminar Series. Bio: Lorraine Grimes is a Postdoctoral Researcher in Applied Social Studies at Maynooth University. Lorraine has a PhD from the National University of Ireland Galway. Her thesis is forthcoming in the form of a monograph with Bloomsbury Academic in 2025 titled ‘Single mothers in Ireland and Britain: Pregnancy, migration and institutionalisation'. Lorraine previously worked with the Digital Repository of Ireland on the Archiving Reproductive Health project which is the subject of this talk. Abstract: Archiving Reproductive Health (ARH) is a Wellcome-funded project coordinated by the Digital Repository of Ireland (DRI), working to preserve digital material created by grassroots organisations working for reproductive justice in Ireland, especially during the 2018 referendum to repeal the Eighth Amendment of the Irish constitution. The project was the first in the world to archive Facebook social media posts. A key part of the project was the archiving of stories posted on a Facebook page called “In Her Shoes”, where people anonymously shared their experiences of being refused abortion care, having to travel or illegally order pills online, and the emotional impact of these experiences. These stories often contained details of traumatic experiences such as sexual assault, obstetric violence and domestic abuse. This talk will introduce the Archiving Reproductive Health Project and archiving sensitive social media material. We will talk about anonymization procedures, coding/cataloguing and developing a self-care protocol and an ethics protocol for the project. Learn more at www.tcd.ie/trinitylongroomhub

Great workshops deliver clarity, improved collaboration, and actionable outcomes.Now, imagine if you and your team could approach every workday with the same high energy and focus as you feel during a great workshop. That's exactly what today's guest is here to help us achieve–building a workshop culture in the workplace.Meet Alison Coward. Alison is the founder of Bracket, a consultancy that partners with ambitious, forward-thinking companies to help them build high-performing team cultures. She is a team culture coach, workshop facilitator, trainer, keynote speaker, and author of “Workshop Culture: A Guide to Building Teams That Thrive” and “A Pocket Guide to Effective Workshops”. Her clients include Google, Meta, Wellcome, and the V&A. With 20 years of experience working in, leading, and facilitating creative teams, Alison is passionate about finding the balance between creativity, productivity, and collaboration so that teams can thrive and do their best work together.In this episode, Alison and I discuss what a workshop culture is, how it differs from traditional workplace models, and how managers can become effective facilitators.She also shares insights into what it looks like for a team to adopt a workshop culture, the behavioral changes that come with this shift, tips for translating workshop principles–like creativity, collaboration, and inclusion—into everyday team practices, and more.Join the conversation now!Get FREE mini-episode guides with the big idea from the week's episode delivered to your inbox when you subscribe to my weekly email.Conversation Topics(00:00) Introduction(02:06) What is a workshop culture?(03:39) Workshop culture vs. traditional work culture(06:12) How managers can become effective facilitators(09:30) Real-world example of a team transitioning to a workshop culture(12:55) Translating big picture ideas into action(14:37) Why every team member is a co-creator of a team culture(17:41) The behavioral changes that come with this cultural shift(21:41) First step in adopting a workshop culture(24:20) How to hold yourself and others accountable for the changes(26:30) A great manager Alison has worked for(27:44) Keep up with Alison(28:14) [Extended Episode Only] The five pillars of a workshop culture(33:26) [Extended Episode Only] What it looks like for teams embracing a workshop cultureAdditional Resources:- Get the extended episode by Joining The Modern Manager Podcast+ Community for just $15 per month- Read the full transcript here- Follow me on Instagram here - Visit my website for more here- Upskill your team here- Subscribe to my YouTube Channel hereKeep up with Alison Coward- Grab a copy of Alison's book: “Workshop Culture: A Guide to Building Teams that Thrive” here- Follow Alison on LinkedIn here- Visit Bracket for more information hereBook Discount: 30% off “Workshop Culture: A Guide to Building Teams That Thrive”Alison is providing members of Podcast+ 30% off her book “Workshop Culture: A Guide to Building Teams That Thrive”. This book will show you how to create a happy and engaged team through small actions which lead to big results. It features a practical and accessible toolkit to help improve your team's performance and productivity.To get this guest bonus and many other member benefits, become a member of The Modern Manager Podcast+ Community.---------------------The Modern Manager is a leadership podcast for rockstar managers who want to create a working environment where people thrive, and great work gets done.Follow The Modern Manager on your favorite podcast platform so you won't miss an episode!

Many non-civil engineers have passed the Civil PE Exam, and our latest guest, Jessica Wellcome, is another awesome example…whose journey is nothing short of inspiring!

A new satire from award winning writer Anita Sullivan, set at a fictional COP conference, with a talking Mosquito. Developed with leading climate scientists.Peter is a hapless politician representing the UK at COP in Paris. Hoping to retire soon – he didn't really want this assignment, but now he's caught like a rabbit in the headlights between the fiercely intelligent business analyst who has taken the place of his usual PA, and the changing landscapes of contemporary politics and climate crisis speak. Will he talk absolute rubbish? Will he keep his job? Will he sell our children's future to the highest bidder? What is African Horse Flu? And can anyone else hear that whining voice?The Mosquito was developed through OKRE Experimental Stories supported by Wellcome, in consultation with Professor Andy Morse (Professor of Climate Impacts at the University of Liverpool) and Dr Omnia El Omrani (Climate and Health Policy Fellow at Imperial College London).Interviews are used with permission from:https://hub.connectingclimateminds.org/lived-experiencesCASTPeter- Robert BathurstThe Mosquito- Laila AljFarah - Laila AljAddy - Audrey BrissonFaith - Ruth EverettMiles - Laurence SaundersThe Volunteer and other roles - Nuhazet Diaz CanoProduction Co-ordinators - Eleri McAuliffe and Noa DowlingSound Design - Catherine RobinsonDirected by John Norton.A BBC Audio Wales production for Radio 4.

Le 4e Sommet Geneva Science and Diplomacy Anticipation (GESDA), qui s'est tenu du 9 au 11 octobre dernier au CERN à Meyrin, a marqué une étape clé dans la préparation des leaders face aux bouleversements scientifiques et technologiques à venir. Parmi les initiatives phares de ce sommet, on trouve le lancement du Global Curriculum for Anticipatory Leadership (GCAL), un programme innovant destiné à former des décideurs capables d'anticiper et de répondre aux avancées technologiques. Ce programme, soutenu par l'organisation caritative Wellcome, propose des formations immersives dans plusieurs grandes villes à travers le monde, dont Madrid, Singapour, Pretoria, Istanbul, et San José au Costa Rica. L'objectif est d'équiper les leaders mondiaux des outils nécessaires pour naviguer dans un monde en rapide mutation. Un autre moment marquant de ce sommet a été le lancement du Geneva Public Portal to Anticipation, une installation interactive créée par Sarah Kenderdine de l'EPFL. Cette plateforme permet aux citoyens de s'immerger dans les percées scientifiques de demain et de mieux comprendre les tendances qui façonneront notre avenir. Enfin, l'introduction de l'Observatoire d'anticipation, un outil inédit, a permis d'identifier les tendances scientifiques émergentes et leur impact sur la diplomatie et la société. Ces initiatives s'inscrivent dans le cadre du programme plus vaste de GESDA, l'Anticipation Gateway, qui vise à démocratiser la compréhension des sciences émergentes et à préparer l'humanité aux défis futurs. Nous avons rencontré Peter Brabeck-Letmathe, Président de la Fondation GESDA, qui nous a partagé son point de vue à l'issue de ce sommet.      

Liam Shaw, Wellcome-funded research fellow at the MacLean Lab in Oxford, delves into the incredible science of forensic palynology where the analysis of pollen is used as evidence.This interview was first broadcast in November 2023.

Air isn't an object, right? Wrong. This week, climate comms expert and historian Dr Alice Bell makes Dan and Kasia think hard about ephemerality via a jam jar of polluted air, captured 'fresh' from the Euston Road in north London. In doing so they explore the history of the climate crisis – where it came from, who covered it up, and when people started noticing we were ruining the only planet we have.  Alice leads us through fog, smog and fumes, answering questions like: why were London's famous “pea-soupers” yellow-tinged (like yellow split-peas), rather than green-tinged? Why was coal dust understood to be a sign of thriving industry and progress? Why did unwell people go to seaside resorts to “take the air”? Which popular English meal was invented purely to give people a social activity indoors, away from the smog? Why have children always been at the forefront of the climate movement, from 1980s episodes of Blue Peter to the school strikes today? What do tobacco and fossil fuel lobbying have in common? Elsewhere, there is talk of Shell: The Musical, whaling ships, Captain Planet, Margaret Thatcher, and an answer to the biggest climate question of all, the one you've all been asking: what does Ludacris have to do with arctic drilling? Dr Alice Bell is Head of Policy for Climate and Health at the Wellcome. Her book ‘Our Biggest Experiment: A History of the Climate Crisis' (Bloomsbury, 2021) is available now, and is captivating, enlightening stuff - get involved! **** For the full-length episode, and 30-odd more exclusive episodes –  please join our Patreon!! ** ONLY £4 A MONTH TO SUPPORT YOUR FAVOURITE CULTURAL HISTORIANS ** **** Theme music: Mr Beatnick Artwork: Archie Bashford

Sub-Saharan Africa accounts for a disproportionate share of global disease-related deaths due to antimicrobial resistance (AMR). Why is it so? Cai Nebe talks to Dr. Janet Midega, Senior Research Manager for Wellcome's Drug Resistant Infections (DRI) program, Basimenye Nhlema, Executive Director at Partners in Health-Malawi and DW correspondent George Mhango in Malawi.

Learn more at TheCityLife.org --- Support this podcast: https://podcasters.spotify.com/pod/show/citylifeorg/support

Wellcome to MMP episode 260. Are you ready to rally?

¡Wellcome a un nuevo capítulo del podcast! En este episodio, hablo sobre cómo poner límites en una nueva estación y por qué es importante no esperar a las anualidades para hacerlo. Os hablo de una lista de temas que quiero tratar en este episodio, a modo de recordatorio. Llevo un tiempo muy a full con las grabaciones en el Lippypodcast, intentando encontrar tiempo para editar todo el material. Este es uno de los proyectos que continuaré ya que me he “dado de baja” de otros proyectos para poder enfocarme mejor. He pasado muchos años trabajando en el mundo del lipedema y he llegado a un punto, un impasse, donde he tenido que hacer una balanza y quiero compartir con ustedes lo que he aprendido. Dar mucho más de lo que recibía a nivel emocional me empezó a agobiar, ya que se me exigía demasiado. Como artista, he diseñado muchas cosas y no me he sentido valorada, no porque no me remuneraran, sino porque me hicieron sentir obligada cuando era un trabajo voluntario. Esto me llevó a un burnout, quedándome bloqueada y saturada. Hasta que me di cuenta que, como persona artista, neurodivergente y creativa, debía cambiar. Antes de llegar a este punto, me encontré con un mundo dividido entre quienes veían mal que yo me “lucrase” por mi arte y quienes lo apoyaban. En este episodio, les contaré cómo me centré en volver a estudiar y algunos detalles sobre mi experiencia en el doblaje. También abordaré la convivencia con la inteligencia artificial, un tema fascinante y muy actual. Además, quiero hablar sobre otros temas y os propongo que participen en las siguientes plataformas para votar y elegir sobre qué les gustaría que hable en los próximos episodios: Lipedema Ilustraciones (mi proceso creativo) La familia Tatuajes Estudio de doblaje Viajes (la experiencia) Cádiz, mi ciudad natal Mi blog, cómo nació Escribir por correspondencia Cómo es ser cuarentona Libros, lectura Películas Podcasting (crear) La música y yo Editar, cómo hago la edición Juegos de mesa Ser la tía preferida de tu sobrino Diferentes grupos de amigos Ser la del medio de tres hermanas Cosas viejunas Cosas catalanas Sueños raros, raros, raros Compartir piso Educación vial para peatones Acento gaditano Refranes Cumpleaños y regalos Obsesión con material de papelería Aprenderse los números de teléfono Nos vemos en las redes!! @labischita Mi pagina de artista diseño: https://arte.bischita.es Mi contacto: https://api.whatsapp.com/message/ABDI332UGBLML1 Mi paypal: https://www.paypal.com/paypalme/sabajanes --- Send in a voice message: https://podcasters.spotify.com/pod/show/labischita/message

Alla vigilia delle elezioni europee del 2024, il fronte delle Destre, più o meno estreme, si presenta più forte che mai, anche grazie all'affermazione in Italia del partito di Giorgia Meloni. "È un fenomeno in atto sotto i nostri occhi, ovunque nel 'Continente nero', che rischiamo di diventare", scrive Francesco Cancellato nel suo ultimo saggio sulla Destra alla conquista dell'Europa, uscito a marzo per Rizzoli. Il tema è stato al centro dell'incontron ell'ambito della prima edizione di Valigia Blu Live durante il Festival Internazionale del Giornalismo di Perugia con il direttore di Fanpage, Francesco Cancellato, la corrispondente da Berlino per la Repubblica, Tonia Mastrobuoni, e il giornalista Stefano Vergine, che per l'Espresso ha contribuito a inchieste internazionali come Panama Papers, Malta Files e FootballLeaks. Regia: Vudio Musica: Ska-p, Wellcome to hell

As the Bill & Melinda Gates Foundation absorbs much of the glory and not nearly enough of the blame, the Wellcome Trust has found a way to maintain a much lower profile in the States while they conduct human experiments on a large segment of the population. Investigative journalist Johnny Vedmore from Unlimited Hangout has been on the trail of the murky philanthropic organization for quite some time, watching and reporting back as they launched the operation in early 2020, then later intentionally drove the COVID narrative into a ditch. What do the people behind the Wellcome Trust actually want for humanity, and is it something that really benefits mankind, or is there a much darker agenda that has remained hidden until now? Anarchapulco 2024 Replay: www.Anarchapulco.com Promo Code: MACRO Sponsors: Chemical Free Body: https://www.chemicalfreebody.com Promo Code: MACRO C60 Purple Power: https://c60purplepower.com/ Promo Code: MACRO Wise Wolf Gold & Silver: www.Macroaggressions.gold True Hemp Science: https://truehempscience.com/ Haelan: https://haelan951.com/pages/macro Solar Power Lifestyle: https://solarpowerlifestyle.com/ Promo Code: MACRO LegalShield: www.DontGetPushedAround.com EMP Shield: www.EMPShield.com Promo Code: MACRO Christian Yordanov's Detoxification Program: https://members.christianyordanov.com/detox-workshop?coupon=MACRO Privacy Academy: https://privacyacademy.com/step/privacy-action-plan-checkout-2/?ref=5620 Coin Bit App: https://coinbitsapp.com/?ref=0SPP0gjuI68PjGU89wUv Macroaggressions Merch Store: https://www.teepublic.com/stores/macroaggressions?ref_id=22530 LinkTree: linktr.ee/macroaggressions Books: HYPOCRAZY: https://amzn.to/3VsPDp8 Controlled Demolition on Amazon: https://amzn.to/3ufZdzx The Octopus Of Global Control: Amazon: https://amzn.to/3VDWQ5c Barnes & Noble: https://bit.ly/39vdKeQ Online Connection: Link Tree: https://linktr.ee/Macroaggressions Instagram: https://www.instagram.com/macroaggressions_podcast/ Discord Link:  https://discord.gg/4mGzmcFexg Website: www.Macroaggressions.io Facebook: www.facebook.com/theoctopusofglobalcontrol Twitter: www.twitter.com/macroaggressio3 Twitter Handle: @macroaggressio3 Rumble: https://rumble.com/c/c-4728012 The Union Of The Unwanted LinkTree: https://linktr.ee/uotuw RSS FEED: https://uotuw.podbean.com/ Merch Store: https://www.teepublic.com/stores/union-of-the-unwanted?ref_id=22643&utm_campaign=22643&utm_medium=affiliate&utm_source

Transformation Tip: “An open door is a welcome that makes a stranger into a friend”This week's strength: Includer Accept others Show awareness to those who are left out Desire to increase the circle Build a sense of community Can tell you when you might be missing What or who can be added to thisNeeds A high need to feel included Blindspots when overusedIf they see others not including people, they can become judgemental of them Want everyone to value the things they doInclude too many peopleThis may slow down the processUnnecessary complicatednessGood positions for them  Wellcome groups Orientation positionsTransformation Application: Think about your workplace or an environment you are often in, think about someone who is excluded, and practice your inclusion. Connect On Social: Podcast Facebook Page Steve Facebook Steve Instagram Steve LinkedIn Pete Facebook Pete Instagram Pete LinkedIn

When COVID-19 struck, the governments of the world weren't prepared, but Bill Gates and his partners were already in place, ready and waiting to move. The largest and most powerful was the Bill & Melinda Gates Foundation, one of the largest philanthropies in the world. Then there was Gavi, the global vaccine organization that Gates helped to found to inoculate people in low-income nations, and the Wellcome Trust, a British research foundation with a multibillion dollar endowment that had worked with the Gates Foundation in previous years. Finally, there was the Coalition for Epidemic Preparedness Innovations, or CEPI, the international vaccine research and development group that Gates and Wellcome both helped to create in 2017. Today we show you the suspects, their motives, the weapons they used to commit the crimes of the pandemic, and how they will execute the next one. On this episode of the NTEB Prophecy News Podcast, we bring you a shocking story made all the more so by the fact that this information comes to us from a Far Left news outlet. Whatever you think you know about Bill Gates masterplan for world domination is about to get a major upgrade. Today we will show you how Bill Gates and the outlets he has funded have been laboring for decades to implement his dystopian eugenics agenda, and how the manufactured COVID crisis in 2020 was the exactly the opening he needed. The COVID crisis established Bill Gates as the de facto authority who decides how pandemics will be fought in the future. Do you find it a comforting thought that medicines like Paxlovid, Remdesivir, and the COVID shots and boosters, given to you by your doctor actually come from organizations financed and controlled by Bill Gates? Not only that, but every major world government, including the World Health Organization and the United Nations, have already ceded control to these 4 groups created by Bill Gates, and we will prove that today. If you fail to grasp what this Podcast will show you, you will be fatally unprepared when the next pandemic arrives, and it's coming sooner than you think.

Vaughn TAN is a consultant, author, toolmaker, and professor of strategy at University College London. For over a decade, Vaughn has helped businesses, not-for-profits, and government agencies — like the Singapore Government, Wellcome, and Carlyle Group — design themselves to flourish in uncertainty. He wrote The Uncertainty Mindset (a book about uncertainty and innovation organizations) and makes idk (a training tool for productive discomfort). He is currently working on building better strategies for different kinds of not-knowing. Vaughn has a PhD in Organizational Behavior and Sociology from Harvard University and Harvard Business School. He previously worked at Google in California on special projects (including spaceflight and big structured data) and consumer products (including Earth, Maps, and Streetview). Learn more about Vaughn: Vaughn's website ⁠Connect on LinkedIn⁠ ⁠See more of his work⁠ Where to find the hosts: Brian Moon ⁠Brian's website⁠ ⁠Brian's LinkedIn⁠ ⁠Brian's Twitter⁠ Laura Militello ⁠Laura's website⁠ ⁠Laura's LinkedIn⁠ ⁠Laura's Twitter⁠

As we begin a new year, what knowledge will help investors prepare for potential volatility on the one hand and potential for opportunities on the other? Jeff Spiegel, U.S. Head of Thematics, Sector, and International ETFs joins host Oscar Pulido to provide a holistic overview of major investment themes, the emergence of the AI trade, opportunities in medical innovation, and the impact of geopolitical shifts on globalization to help investors navigate the year ahead.Sources: Slalom, “AI's most powerful prompt,” 10/10/23; BlackRock, Morningstar, BlackRock Portfolio Solutions as of June 30, 2022. Starting Portfolio Allocation is representative of advisors' broad asset allocations for equities, based on analysis of 21,276 portfolios over the 12-month trailing period; Inter Press Service News Agency, “The Historic Reversal of Populations,” 08/08/2016; BlackRock, “Diagnosis: Big opportunity in healthcare stocks,” 07/27/2023; Fortune, “Scientists just used A.I. to map a fruit fly's brain. Here's why it's a ‘turning point in neuroscience',” 07/08/2023; Drug Discovery and Development, “The Brain Knowledge Platform aims to illumine the brain's cellular universe,” 06/10/2023; Morgan Stanley, “Why Artificial Intelligence Could Speed Drug Discovery,”09/09/2023; BCG and Wellcome, Unlocking the potential of AI in Drug Discovery,” June 2023; Gartner, “Beyond ChatGPT: The Future of Generative AI for Enterprises,” 01/26/2023; World Economic Forum, “This chart shows the growth of India's economy,” 09/26/2022; The Economic Times, “India set to be world's third-largest economy by 2030: S&P Global,” 10/25/2023; Global Business Intelligence, Bloomberg, as of 10/31/23; Morningstar, as of 10/31/2023.This content is for informational purposes only and is not an offer or a solicitation. Reliance upon information in this material is at the sole discretion of the listener. In the UK and Non-European Economic Area countries, this is authorized and regulated by the Financial Conduct Authority. In the European Economic Area, this is authorized and regulated by the Netherlands Authority for the Financial Markets. For full disclosures go to Blackrock.com/corporate/compliance/bid-disclosuresSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Wellcome back, This is the continued part of the conversation had between Allen and I. Enjoy. Links: Podcast Notes ---------- [ https://docs.google.com/document/d/e/2PACX-1vS5qPesNslGRURO4NmElVe4_ZYhUBSFlq9yJXFQ7_T7dTDrnIDxg7HyNvtX-inHPx8jFJoA3jFHQuum/pub ] IG ---------- [ ⁠⁠⁠⁠⁠⁠https://bit.ly/IG-LTS⁠⁠⁠⁠⁠⁠ ]LTS Email & Inquiries ---------- [ ⁠⁠⁠⁠⁠⁠lifetechsundry@gmail.com⁠⁠⁠⁠⁠⁠ ]LTS X (Formerly Twitter) ---------- [ ⁠⁠⁠⁠⁠⁠https://bit.ly/LTSTweets⁠⁠⁠⁠⁠⁠ ]Donate To LTS ---------- [ ⁠⁠⁠⁠⁠⁠https://bit.ly/LTSDonos⁠⁠⁠⁠⁠⁠ ]Buy Me Coffee ---------- [ ⁠⁠⁠⁠⁠⁠https://www.buymeacoffee.com/LTS2020⁠⁠⁠⁠⁠⁠ ] --- Send in a voice message: https://podcasters.spotify.com/pod/show/ltspodcast/message Support this podcast: https://podcasters.spotify.com/pod/show/ltspodcast/support

In this episode, our guests tackle snakebite, a topic suggested by one of our research partner organizations, the Oswaldo Cruz Foundation (Fiocruz) in Brazil. While snakebite is a neglected public health issue, the World Health Organization (WHO) estimates that each year, 5.4 million people are bitten by snakes, and up to 137,880 people die from snake bites. Host Garry Aslanyan speaks with Fan Hui Wen and Thea Litschka-Koen, snakebite gurus in Brazil and Eswatini, respectively, who reveal untold truths about snake bites in their communities and the complexities associated with producing and administering antivenom. Diogo Martins, the research lead for snakebite at Wellcome in the United Kingdom, makes the case for why we should consider snakebite a global health issue.Related episode documents, transcripts and other information can be found on our website.Subscribe to the Global Health Matters podcast newsletter.  Follow @TDRnews on Twitter, TDR on LinkedIn and @ghm_podcast on Instagram for updates.  Disclaimer: The views, information, or opinions expressed during the Global Health Matters podcast series are solely those of the individuals involved and do not necessarily represent those of TDR or the World Health Organization.  All content © 2023 Global Health Matters. 

The writer and academic Emma Dabiri encourages unruliness in her latest book, Disobedient Bodies. She puts the origins of western beauty ideals under the spotlight and explores ways to rebel against and subvert the current orthodoxy. The book is accompanied by an exhibition, The Cult of Beauty, at the Wellcome Collection from 26 October 2023 to 28 April 2024. It was in the Wellcome's archive that the filmmaker Carol Morley came across the works and writings of the artist Audrey Amiss. In her new film, Typist Artist Pirate King, Morley creates an imaginative tribute to an unjustly neglected and misunderstood artist. The norm in the world of medical research has been the male body, but in her latest work the scientist and author Cat Bohannon focuses exclusively on women. In Eve: How the Female Body Drove 200 million Years of Human Revolution she looks at everything from birth to death. Producer: Katy Hickman

Throughout this podcast series, we've met trailblazing scientists and researchers changing the world, alongside the people who have inspired and contributed to their work.  In this final bonus episode, Julia Gillard, Chair of Wellcome, brings together three experts from the series to reflect on the main themes that have emerged and ask what challenges still lie ahead in the field of global health. When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information and transcripts visit wellcome.org  

During the Covid-19 pandemic, the benefits of sequencing infectious disease pathogens became more visible than ever before. The possibilities are huge: genomic sequencing is allowing scientists to unlock the secrets of disease prevention, helping dispel myths and stigma around disease outbreaks as well as allowing governments to act in real-time with targeted and often low-cost interventions.  In this episode Alisha speaks to Professor Christian Happi, Director of the African Centre of Excellence for Genomics of Infectious Diseases, about his pioneering use of the technology during the 2014 Ebola outbreak in Nigeria which identified the origin of the virus. They hear from the lead researcher who used sequencing to map a subsequent outbreak in Guinea, changing how healthcare workers understand the disease. When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information and podcast transcripts visit wellcome.org

Wellcome to the show where Josh, Noah, and Jenna get together and make it happen with some fun topics from Oliver Anthony and his rise to fame, dream jobs you would like to have where money wasn't the driving force, and Starbucks officially told us its fall y'all. so be sure to tune in and give it a listen, and don't forget to leave a rate and review so that we can bless some ear holes. Please and Thank You --- Send in a voice message: https://podcasters.spotify.com/pod/show/joey-butsch/message

Poor mental health has always been associated with lower socio-economic status, but what if you turned the idea on its head and administered cash transfers as a mental health treatment in and of itself? The scientific research community has long grappled with the lack of major breakthroughs in the treatment of mental health disorders. So could cash transfers hold the key to coming up with a universally applicable and low-cost mental health intervention?  In this episode Alisha is in conversation with Professor Vikram Patel, a world leader in global mental health, who explains the challenges researchers have faced globally in the fight against poor mental health, and the potential of using cash transfers. They hear from an early beneficiary of Brazil's Bolsa Familia cash transfer programme and meet the professor developing a pioneering new study with young people in Nepal, South Africa and Colombia. When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information and podcast transcripts visit wellcome.org 

With rising temperatures and shifting climates imperilling our crops, the food chain – from planting to consumer – is under threat. This could lead to higher food prices, poor nutrition, hunger and migration. Alisha is in conversation with Professor Ruth Defries, a global expert in ecology and sustainable development, to discuss how the world has become reliant on a small number of crops such as corn and rice, leaving us in a vulnerable position if these staples do not grow well as the planet heats. So how can we encourage climate resilience through crop diversity? They hear from a multi-country research project which is exploring whether indigenous crops could hold the key to creating more sustainable food systems, and meet a South African farmer who is helping keep these old growing traditions alive.  When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit wellcome.org

It may seem obvious that a lack of sleep can exacerbate poor mental health - whether a symptom, cause or both, the two go hand in hand. But until very recently, there was little scientific research to back this idea up – and as a result, sleep treatments have been overlooked as a potential remedy for poor mental health. Prof Daniel Freeman is a clinical psychologist who's trying to change that. He's leading studies into the effectiveness of sleep treatments for people experiencing psychosis and getting positive results.   In this episode, Alisha speaks to Prof Freeman about the importance of sleep, its potential in fighting the global mental health crisis, and some of the surprisingly simple techniques that can aid a better night's rest. They hear from Ryan, who saw a dramatic shift in his mental health after taking part in one of Prof Freeman's studies.  If you have been affected by the topics discussed in this episode, befrienders.org can help you find a support service local to you.  When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast. 

When Danish geneticist, Professor Eske Willerslev led the team that sequenced the first ancient human genome in 2010, he opened up a world of research possibilities with global significance. But this potential comes with risk. Research into DNA from ancient remains can upend understandings of history and ancestry within living indigenous communities and violate cultural sensitivities.  On this episode, Alisha speaks with Eske alongside Shane Doyle, a member of the Crow Tribe in Montana, USA. Eske and Shane have turned a collaboration into a friendship that demonstrates the power of an exchange between ancient customs and emerging science. Together they discuss the possibilities and the pitfalls of ancient DNA research, and how to build mutual trust and respect between indigenous communities and scientists. When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

Vaccines are formidable tools against infectious disease. But the success of a vaccine in one part of the world doesn't guarantee similar outcomes elsewhere. That's where human infection studies come in – where volunteers, closely monitored by researchers, receive a vaccine and are subsequently given a small dose of an infectious disease. This might sound worrying, but it is a quick and effective way to get data about whether a vaccine is working. Alisha speaks with Dr Dingase Dula, who researched a pneumococcal vaccine in Malawi, to learn more about the impact of infection studies. They also meet Becky Mkandawire and Stonard Mwale, who volunteered to take part in the study. They discuss the role of trust in human infection studies, what it's like to be part of one, and the importance of African-led research in combating infectious disease. When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

Around the world, roughly one billion people live in informal settlements – residential areas that fall outside the jurisdiction of governments. These communities live without traditional centralised sanitation and water systems. As a result, the settlements are vulnerable to extreme weather events like floods, which cause wastewater to spread through homes and lead to serious health issues.  As climate change and nearby development increase the frequency and severity of floods in these settlements, organisations like RISE (Revitalising Informal Settlements and their Environments) are trying to help. In this episode, Alisha speaks to Professor Karin Leder, head of research at RISE, about projects in Indonesia and Fiji that are collaborating with local communities to combine scientific study with infrastructure-building. They hear from Losalini Malumu and Ibu Ina Rahlina, RISE staff members and residents of informal settlements, who through their experiences demonstrate the critical role of collaborating with those most affected by these challenges.  When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

The world's wealthiest medical research foundation, Wellcome Trust, long disguised as an altruistic charity organization committed to helping humanity, has been knee-deep in the COVID corruption and has major and long-lasting ties to the British eugenics movement. With over $40 billion in funds, the organization has invested heavily in vaccine development and has been instrumental in providing shots to the developing world with the help of the Bill & Melinda Gates Foundation. The most concerning aspect might be the development of the Wellcome Leap program that seeks to become the pharmaceutical version of America's DARPA. With seed funding of $300 million and the former heads of DARPA leading the way, will Wellcome Leap become a savior for humanity or the group that extinguished it? Sponsors: Emergency Preparedness Food: www.preparewithmacroaggressions.com Chemical Free Body: https://www.chemicalfreebody.com and use promo code: MACRO C60 Purple Power: https://c60purplepower.com/ Promo Code: MACRO Wise Wolf Gold & Silver: www.Macroaggressions.gold True Hemp Science: https://truehempscience.com/ Haelan: https://haelan951.com/pages/macro Solar Power Lifestyle: https://solarpowerlifestyle.com/ Promo Code: MACRO LegalShield: www.DontGetPushedAround.com EMP Shield: www.EMPShield.com Promo Code: MACRO Coin Bit App: https://coinbitsapp.com/?ref=0SPP0gjuI68PjGU89wUv Macroaggressions Merch Store: https://www.teepublic.com/stores/macroaggressions?ref_id=22530 LinkTree: linktr.ee/macroaggressions Books: HYPOCRAZY: https://amzn.to/3VsPDp8 Controlled Demolition on Amazon: https://amzn.to/3ufZdzx The Octopus Of Global Control: Amazon: https://amzn.to/3VDWQ5c Barnes & Noble: https://bit.ly/39vdKeQ Online Connection: Link Tree: https://linktr.ee/Macroaggressions Instagram: https://www.instagram.com/macroaggressions_podcast/ Discord Link:  https://discord.gg/4mGzmcFexg Website: www.theoctopusofglobalcontrol.com Facebook: www.facebook.com/theoctopusofglobalcontrol Twitter: www.twitter.com/macroaggressio3 Twitter Handle: @macroaggressio3 YouTube: www.youtube.com/channel/UCn3

Psychosis is one of the most severe, and most stigmatised, mental health conditions. But what if technology could help us spot the signs early on? Could more accurate prediction help guide earlier intervention, to produce better outcomes for people at risk of psychosis? Alisha is in discussion with Professor Iris Sommer, a global leader in the psychosis field to examine exactly where the understanding of the condition is, whether we're approaching treatment in an equitable way, and how we can ensure earlier diagnosis and better treatment.   They hear from a therapist in Brazil, Dr Alexandre Loch, and his patient Tammy about how hard a diagnosis can be, and why it can often come too late to prevent the onset of severe symptoms. Alexandre also shares his innovative work using AI to spot whether someone might be at risk of developing psychosis, hinting at a potentially transformative breakthrough.  When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

Since the discovery of penicillin in the early 20th century, we've seen the risk of minor infections virtually disappear. But after years of antibiotics being abused and overused, we now face a silent pandemic where the treatments we rely on no longer work.  The potential scale of antimicrobial resistance, or AMR, is staggering, and there is a lack of awareness of just how dangerous it could be. Alisha speaks to Dr Anand Anandkumar, an engineer turned biotechnologist, to correct the misconceptions around AMR, and discover what we can do about it. We'll also hear from John Kariuki in Kenya, whose own experience with AMR almost cost him his life, and Benard Wanyama, whose project is treating patients with infections and monitoring the spread of AMR.  Together, they make a powerful case for urgent and collective action to stem the tide of superbugs.   When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

In the 1970s, when a heterosexual couple divorced, courts almost always awarded child custody to the mother, except in one scenario: when the mother had come out as a lesbian.   Professor Susan Golombok was determined to challenge these prejudices and to shine a light on the realities of same-sex parenting. She began studying a range of different family structures to build up a body of evidence which, over the course of her life, has had a tangible impact on everyday families around the world  In this episode, Alisha is in conversation with Susan about the influence and breadth of her work, from broadening societal perceptions to changing laws. We also hear from a couple who took part in the research and learn why it was so important to them, and the legacy it has left for families everywhere.   When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

As the world gets hotter and hotter, so do we - and just like crops and wildlife, we're struggling to cope with what extreme heat does to our bodies. Every year temperatures reach new records, and the way we live, work and rest are changing to accommodate it.   Kathy Baughman McLeod, director of the Adrienne Arsht Rockefeller Foundation Resilience Centre and chair of the Extreme Heat Resilience Alliance, talks Alisha through the realities of what heat stress does to us, how workers across the globe - from India to the US - are feeling the heat, and the tangible solutions being implemented globally to increase resilience. They discuss how women are disproportionately affected by this issue, and hear from the market traders of Freetown, Sierra Leone, a city on the front line of the climate crisis. They also meet the capital's Chief Heat Officer, who's part of an international network of women working to protect their city's most vulnerable communities from the risks of rising temperatures.  When Science Finds a Way is brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. For more information visit www.wellcome.org/news-and-reports/podcast.

Join botanist-turned-Hollywood actor Alisha Wainwright as she meets the trailblazing scientists and researchers changing the world, alongside the people who have inspired and contributed to their work.  From community-led climate change solutions, to cutting edge technology that's redefining disease, and fresh approaches to treating mental health disorders, When Science Finds a Way will show you a world of creative solutions from people at the heart of the greatest health challenges of our time.   When Science Finds a Way launches on 28th June 2023. Brought to you by Wellcome, an independent global foundation that supports science to solve the urgent health challenges facing everyone. Please visit wellcome.org for more information. 

Wellcome back to the beauty and the network podcast. hosted by bridal beauty team owner Jasmine Jones, licensed cosmetologist since 2013. This podcast is the perfect place for bridal beauty pros who are looking to integrate sustainable systems, routines, and strategy into their business to grow a team, hire help and save time in your backend so you have a life outside of business. In today's episode i shared the 3 habits that helped me throughout my journey from a new freelance bridal beauty pro, to freelancing for bridal beauty teams to owning my own. I needed to shift who i was being in order to make my dream become a reality for me. I wanted to share the process i went through so you can see what habits or routines might serve you based upon the level of growth in your business. The 3 main habits i mentioned today were 1.Writinging tings down 2.Creating a check in point for yourself 3.Eliminating Distractions tune in to the episode so see how i put these habits in use to help me grow! Helpful links Follow me on Instagram Bridal Beauty Business Growth Coach|Systems & Wellness (@beautyandthenetwork) • Instagram photos and videos Join The Membership Membership — Beauty and the Network online coaching for bridal beauty pros & service-based business owners Free Facebook Community (4) Beauty And The Network (Open Community) | Facebook

Mark Henderson, Director of Corporate Affairs at Wellcome, joins Edelman's Justin Blake to unpack findings from the 2023 Edelman Trust Barometer Special Report: Trust and Health and to give insights on how Wellcome builds trust on health issues through communication. “People will trust when they're treated as equals rather than as passive vessels for information,” … Continue reading "Mark Henderson on Communicating Trusted Health Information"

In 1856, an American woman called Eunice Newton Foote discovered that higher levels of carbon dioxide would warm the planet. But credit for discovering climate change was given to someone else who made the same discovery three years later. We celebrate Foote's role in early climate science by recreating her little-known experiment and asking if there are some voices that continue to be overlooked in climate science today – and how we overcome these climate blind spots? Presenter Graihagh Jackson is joined by: Dr Alice Bell, Head of Climate and Health Policy at Wellcome and author of ‘Our Biggest Experiment – An Epic History of the Climate Crisis' Professor Regina Rodrigues, Professor of Physical Oceanography and Climate at the Federal University of Santa Catarina in Florianopolis, Brazil. Professor Andrea Sella, Professor of Chemistry at University College London. Producer: Louise Parry Researcher: Louise Byrne Series Producer: Alex Lewis Editor: Richard Vadon Sound Engineer: Graham Puddifoot Email us: theclimatequestion@bbc.com

We are a teeming mass of interconnected microbes and the impact of this microscopic universe on our health, our minds, even our moods, is profound. Made in collaboration with Wellcome Collection, Claudia Hammond and an expert panel explore one of the fastest moving areas of science and what it means for modern medicine. Recorded in front of a live audience at Wellcome's Reading Room in London, Claudia discovers how our microbes could be harnessed to improve our mental and physical health. And along with the scientific insights, there are important answers to questions everybody wants to know the answer to, such as why some peoples' “emissions” smell so badly and how having a dog or cat enriches your microbiome. On stage with Claudia are immunologist Professor Sheena Cruickshank from the University of Manchester, microbiologist Professor Glenn Gibson from the University of Reading and neuroscientist Professor John Cryan from University College Cork in Ireland. Produced by: Fiona Hill and Elisabeth Tuohy Studio Engineer: Bob Nettles and Emma Hearth Image: Scanning electron micrograph (SEM) of bacteria cultured from a sample of human faeces. Credit: Steve Gschmeissner/Science Photo Library/Getty Images

Hey Canners!Wellcome to another episode of the jacked and canned sports rountable episode ! 

Stefanie Posavec is a designer, artist, and author whose practice focuses on finding new, experimental approaches to communicating data and information. This work has been exhibited internationally at major galleries including the V&A, the Design Museum, Somerset House, and the Wellcome... The post Episode #232: Stefanie Posavec and Sonja Kuijpers appeared first on PolicyViz.

Infectious diseases are the second leading cause of death worldwide, killing tens of millions of people every year. COVID-19 alone has killed more than 6.8 million people, according to Johns Hopkins University. Drug-resistant superbugs directly kill 1.27 million people a year, according to one recent prominent study.Surely drug companies are all over this potentially lucrative market, with so many diseases to fight and treat?  However, they aren't. The US Food and Drug Administration has not approved a new antibiotic since 2019, and only one truly new antibiotic has been approved since 1987.It's partly because the money just isn't there. Companies making cancer drugs raised about $7 billion in funding in 2020, while companies making antibiotics raised a fraction of that – just $160 million. Plus, it's hard to bring a new drug to market. The National Institutes of Health estimates 90% of experimental drugs never even make it to testing in humans.In this episode, we are chatting with Kevin Outterson, a professor of law at Boston University and the founding Executive Director and Principal Investigator of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator or CARB-X, a global nonprofit partnership funded by the U.S., U.K., and German governments; Wellcome; and the Bill & Melinda Gates Foundation.Professor Outterson argues that antibiotics should be treated as infrastructure, and companies making new drugs to fight antimicrobial-resistant bacteria, viruses, and fungi –often called superbugs – should be treated as vital government contractors and paid upfront for the work they do that could save tens of millions of lives. Listen as he describes the problem, and potential solutions, with One World, One Health host Maggie Fox.

Wellcome to the Hellmouth! This week Mike is joined by Joshua Tonks and Alex Ayling to discuss the world of Buffy! We begin with a deep dive of the original 1992 movie, followed by an in-depth discussion of both the Buffy TV show (1997 - 2003) and it's spin-off, Angel (1999-2004).  Music by Jack Whitney.  Visit our website www.evolutionofhorror.com  Buy tickets for our next upcoming EVOLUTION OF HORROR PRESENTS screening at the Genesis Cinema! www.evolutionofhorror.com/genesis You can now buy Evolution of Horror merch on our TeePublic store! www.evolutionofhorror.com/merchandise Subscribe and donate on PATREON for bonus monthly content and extra treats... www.patreon.com/evolutionofhorror  Email us!  Follow us on TWITTER Follow us on INSTAGRAM Like us on FACEBOOK Join the DISCUSSION GROUP Join the DISCORD Follow us on LETTERBOXD Mike Muncer is a producer, podcaster and film journalist and can be found on TWITTER  

Six and a half million dead. More than a hundred times that infected. The Covid-19 pandemic has wreaked havoc across the globe. But in the final months of the third year of this health crisis, some now claim it's all over. Scientists with key roles in the global response join Claudia Hammond to consider the evidence behind the declarations that the pandemic has finished and they set out how, officially, this global health crisis will be brought to an end. They reject claims that the pandemic is over, but say the emergency phase of this global health crisis is coming to a close. But only if countries remain vigilant and maintain pandemic preparedness. If vaccines reach arms, if treatments are shared equally and if nations re-introduce public health measures like mask wearing and social distancing when the inevitable new waves (and potential new variants) emerge, the appalling loss of life we saw at the beginning of the pandemic, they tell Claudia, won't be repeated. There are stark warnings too that the dramatic global drop in the sequencing of virus samples (which enables us to see how the virus is evolving) is posing a serious risk. We can't react to a new threat, Claudia's panel say, if you can't see it. Sequencing, as well as testing, has fallen by 90% since January this year, from 100,000 weekly sequences ten months ago to less than 10,000 now. This severely limits the ability to track the known variants (currently 200 sub-lineages of the Omicron variant). Produced in collaboration with Wellcome and recorded in front of a live audience in Wellcome's Reading Room in London, Claudia's expert panel includes Dr Maria Van Kerkhove, the World Health Organisation's Technical Lead for Covid-19, Professor Salim Abdool Karim, co-chair of the south African Ministerial Advisory Committee on Covid-19 and a member of the Africa Task Force which oversees the African continent's response to the virus and Professor Sir Jeremy Farrar, the Director of Wellcome and a former adviser to the UK government on its Covid response. Presenter: Claudia Hammond Produced by: Fiona Hill and Maria Simons Studio Engineers: Giles Aspen and Emma Harth